Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
synergistic cell cycle repression by hdac ezh2 co targeting in h3k27 altered diffuse midline glioma
Original title: “Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.”
chimeric antigen receptor t cell therapy for pediatric and young adult primary central nervous system tumors a systematic review of early phase clinical trials with a focus on diffuse midline glioma
Original title: “Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.”
dordaviprone for diffuse midline glioma a landmark approval or a premature step
Original title: “Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?”